TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gastric Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of anti-pseudomonal β-lactam therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mini Assisting Hand Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Loss of >2 Lines for Best Spectacle Corrected Visual Acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one year graft survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Flap Failure and Compromise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue Saturation Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of objective disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity, specificity, and accuracy in predicting CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: UHDRS SIF ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence and severity of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resting Motor Threshold (RMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cytokine Levels in Serum and bronchoalveolar fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activation Status of immune cells from blood and bronchoalveolar fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alarmins in Serum and bronchoalveolar fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vaccine-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Exogenous insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histology scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in serum phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in TmP/GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rickets score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in nephrocalcinosis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Specific detection of SARS-CoV-2 specific RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dietary intake of nutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency and severity of treatment-emergent SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC (0 - ∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glycosylated Hemoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sympathetic Nerve Activity Burst Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sympathetic Nerve Activity Burst Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to resolution of CMO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wall motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary ventilation/pulmonary blood flow (V/Q in l/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Movement Disorder Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columbia Suicide Severity Rating Scale (C-SSRS) Responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time elapsed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of necessary interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients achieving a positive clinical benefit response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Reported Primary Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Reporting Proximal Impacts-Physical Impact
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Reporting Distal Impacts-emotional Impact
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Participants Experiencing Clinically Significant Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Effective Dose of Riluzole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSV Load in the Upper Respiratory Tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of arterial Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Retinal Microvasculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in heart rate to orthostatic loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in blood pressure to orthostatic loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in stress levels via cortisol measurements from hair samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in The Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean Number of Days of Decrease in Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pre-specified Infusion Associated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: rate of successful self reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate Based on Modified Response Evaluation Criteria In Solid Tumors (mRECIST) v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of Response (DOR) Based on mRECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fragmentation rate of Troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain metabolism measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Minutes of moderate-intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of asciminib by AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of asciminib by AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of asciminib by Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of asciminib from plasma by CL/F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Lipid Layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Utility
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Trough Seated Diastolic Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Full Recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of affective symptoms after 1 year of PAP treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of anxiety symptoms after 1 year of PAP treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Controlled Oral Word Association Test after 1 year of PAP treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in d2 Test after 1 year of PAP treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Trail making test after 1 year of PAP treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Retention rates of adalimumab, etanercept and infliximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood flow measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: oxygenation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Feasibility/ Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility/ Retention in Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility/ Retention in the Program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: alpha 1-adrenoceptor vasoreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of ovulation induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Plasma MMPs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: DASH score at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of non fibrous mineral particles in LBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: neonatal cord acid-base status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neonatal transcutaneous bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infants with neonatal jaundice requiring phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infants with neonatal hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in complete spontaneous bowel movements (CSBM)/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase of at least one CSBM per week for 9 or more weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Standardized uptake value of 68Ga NEB in lymphatic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accrual of participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to metabolic support
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Highest VAS score in recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Axonemal Dynein Heavy Chain 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Edinburgh Postpartum Depression Scale (EPDS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: T and B cell function defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psychophysiological reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time of correct response in N-back task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New pregnancy after study entry
Endpoint domain: Mortality/survival
Primary endpoint: Any health encounter for injury or ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of well-child visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Injections Per Patient Per Season
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Body Site of Injections Per Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Interval Between Administrations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dosage Per Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of events 'hospitalization and death'
Endpoint domain: Mortality/survival
Primary endpoint: Partial tear of supraspinatus tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decision to Proceed With Septal Reduction Therapy (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SRT Guideline Eligible at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gestational Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Resting Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in electrophysiological activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline short physical performance battery at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline gait speed at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of community-level HIV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in HIV care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low attenuation plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with adverse events following the administration of TMC647055
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed plasma concentration of TMC647055
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve (AUC) of TMC647055
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Discontinuing Study Drug Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) For All Participants in Cohorts 1 and 3
Endpoint domain: Physiological/clinical
Primary endpoint: Time to confirmed diagnosis of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Endocrine toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Differences in immune cell populations (macrophages/Tcells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nasal Congestion/Obstruction Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal Polyp Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adverse events (AEs) or serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with abnormal change from Baseline in laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with Optimally Tolerated regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in asthma knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily occurrence of Heavy Drinking Days (HDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angles measured in degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lines measured in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcutaneous Oxygen Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transcutaneous Carbon Dioxide Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Circulating ICAM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of systemic filling pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in dating violence perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Change in dating violence victimization
Endpoint domain: Adverse events/effects
Primary endpoint: changes in clinical response measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of febrile events during induction
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Epithelial Ingrowth Under LASIK Flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function as measured by ADAS Cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurocognitive Testing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Meeting Depression Remission Criteria
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Colposcopic Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Accrual
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intervention Fidelity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability and Satisfaction with Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Engagement with Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dropout Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of ESBL-colonized individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incisional hernia and burst abdomen rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of extreme toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adhesion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: average adherence under NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in chronic Banff scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative or Average Slow-wave Activity (SWA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Visual Impairment Measured by Visual Functioning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Eyes Showing Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Detect Progression Measured in Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving 75% improvement in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pathologic Complete Response Rate (PCRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: TMS assessment of resting motor threshold (RMT) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive assessment change applying Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Psychological assessment change applying Fatigue Severity Scale (FSS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Headache pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peritoneal membrane function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of toxicity incidents
Endpoint domain: Adverse events/effects